Sara Benolkin

About Sara Benolkin

Clinical researcher since 2001, conducting studies from Phase I first-in-human to Phase IV long-term safety studies, Real World Evidence, and registries, with an emphasis in Rare Disease, Pediatrics, and Cell & Gene Therapy. Currently Director of Therapeutic Science & Strategy for Pediatric and Rare Disease for IQVIA, where my experience in clinical trial strategy and delivery pairs with my passion to implement a patient-centered approach to develop meaningful treatments for patients and families affected by rare diseases.

Experience

1. Director, Therapeutic Science & Strategy - Rare Disease and Pediatrics

   IQVIA

   Feb 2022 — Present

   Ownership of client relationships in close collaboration with the sales and account team, with responsibility for securing and growing business in Rare Disease and Pediatrics, client satisfaction, project margin, and differentiation of services across business units, where we were at 106% of the target for new business awards for 2023Leverages extensive global data intelligence and drives the development and delivery of proposals with market leading solutions and capabilities with a special focus on reducing the burden and unmet need of Rare Disease patients and families and the sites/experts that treat themServes as a therapeutic and operational strategy expert throughout the new business and program project delivery lifecycle to increase therapeutic market share with strategies that meet or exceed timelines and budgetTranslates the therapeutic and operational strategy to the project teams once new business is awardedLeads cross functional teams in designing strategies and solutions, including advising on global regulatory with Regulatory Affairs and Drug Development Solutions (RADDS)Lead member of the Pediatric and Rare Disease Center of Excellence (PRDCOE), including contributing to Rare Disease Day activities, Patient Advocacy Group engagement, World Orphan Drug Congress and other conference representation, website updates, thought leadership, internal consulting and trainingAdvise on strategic site relationships for our Prime/Partner/Super-Partner and Pediatric and Rare Disease Site NetworksNominated for and completed Emerging Leadership Program (VP training program, upper 2.7% high performing directors), Aug-Nov 2023Won IQVIA Therapeutic Science and Strategy Unit “Dream Team Award” for winning a partnership with a Cell and Gene Therapy sponsor, 2022Completed 6 Sigma Lean Practitioner Training Certification, May 2022

Education

• Baylor University

  BS, Pre-Med

  1995 — 1997

• Texas A&M University

  BA, Pre-Med (Biology Major, Chemistry Minor)

  1997 — 1999